![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/55458d8a-6e53-43a3-abb0-e72e5acba138/gr1.gif)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![COVID-19 vaccines – The difference between the third dose and a booster dose – Easy Read | Australian Government Department of Health and Aged Care COVID-19 vaccines – The difference between the third dose and a booster dose – Easy Read | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/images/publications/2021/11/covid-19-vaccines-the-difference-between-the-third-dose-and-a-booster-dose-easy-read.png)
COVID-19 vaccines – The difference between the third dose and a booster dose – Easy Read | Australian Government Department of Health and Aged Care
![Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health](https://publichealth.jhu.edu/sites/default/files/styles/social_image/public/2023-02/bivalent-vaccine-g1422104879.jpg?itok=mgeH3XVw)
Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)